Description
Tirzepatide Capsules | GIP/GLP-1 Dual Agonist — Metabolic Research
Tirzepatide is an FDA-approved dual agonist of glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R), marketed as Mounjaro (T2D) and Zepbound (obesity). It demonstrated 22.5% weight loss in the SURMOUNT-1 trial. These capsules (10mg per capsule, 30 capsules) provide an oral research format for mechanistic studies comparing the GIPR+GLP-1R dual pathway against standalone GLP-1 agonists.
Mechanism of Action
- GLP-1R agonism — enhances insulin secretion, suppresses glucagon, delays gastric emptying, and reduces food intake via hypothalamic circuits
- GIPR agonism — additively stimulates insulin secretion and contributes to weight loss through central GIPR-expressing neurons
- Beta-cell preservation — preclinical data suggest improved beta-cell function and mass maintenance
- Adipose-specific effects — GIPR agonism may directly modulate white adipose tissue lipolysis beyond GLP-1 actions
Research Areas
Tirzepatide capsules are studied in type 2 diabetes, obesity, NAFLD, and incretin biology. Compare with Retatrutide capsules (triple agonist adding glucagon receptor) for comprehensive incretin pathway research.
For Research Use Only. Rainbow Peptide supplies this compound exclusively for in vitro and laboratory research purposes. Not for human or veterinary use.
Dr. M. Vasquez –
Tirzepatide capsules for our oral GLP-1/GIP dual agonist bioavailability research. Content purity >99% confirmed. Capsule uniformity excellent. COA detailed. Oral receptor activation model showed detectable dual incretin activity.
R. Johansson –
10mg Tirzepatide capsules — well-suited for oral bioavailability studies. Content confirmed. COA thorough. Our in vitro GLP-1R activation model showed dose-dependent response from capsule dissolution.
A. Osei –
Good Tirzepatide capsules. Content >98.5%. Capsule uniformity within spec. COA comprehensive. Practical oral format for our GLP-1/GIP agonist research.